NCT07611240Recruiting
Sevoflurane vs Propofol Anesthesia in Obese Patients Undergoing Lumbar Surgery
Comparison of the Immunomodulatory Effects of Sevoflurane and Propofol Anesthesia on Pentraxin-3 and Serum Amyloid A Levels in Obese Patients Undergoing Lumbar Instrumentation Surgery
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
This randomized, single-center, single-masked clinical trial aims to compare the immunomodulatory effects of sevoflurane-based inhalational anesthesia and propofol-based total intravenous anesthesia in obese patients undergoing elective lumbar instrumentation surgery. Seventy patients will be randomized into two groups: a propofol group and a sevoflurane group. Blood samples will be collected preoperatively, at postoperative 6 hours, and at postoperative 24 hours. Pentraxin-3 and serum amyloid A levels will be evaluated as primary inflammatory biomarkers together with IL-6, TNF-α, CRP, glucose, and complete blood count parameters.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 7 May 2026
- Start date
- 15 Jun 2025
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Ataturk University
- Diseases
- Obesity
- NCT number
- NCT07611240
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 15 Jun 2025 to the primary completion date, 15 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery within the last 3 months
- Chronic anti-inflammatory or immunomodulatory drug use
- Emergency surgery
Other illness
- Known allergy to inhalational or intravenous anesthetic agents
- Acute or chronic infectious disease
- Autoimmune disease or immunodeficiency
- History of malignancy or active cancer treatment
- Diabetes mellitus, metabolic syndrome, or insulin resistance
- Neurological disease, including epilepsy, multiple sclerosis, or Parkinson's disease
- Known allergy to study drugs (propofol, sevoflurane, remifentanil)
Lab values
- Renal failure, defined as GFR \<60 mL/min
- Liver failure, defined as AST or ALT greater than 2 times the upper limit of normal
Other
- Morbid obesity, defined as BMI \>35 kg/m²
- Pregnancy or lactation
- Alcohol or substance abuse
- Inability to comply with the study protocol or provide informed consent
Who the study is looking for
- Patients aged between 18 and 65 years
- Patients scheduled for elective lumbar instrumentation surgery
- Body mass index between 30 and 34.9 kg/m²
- Patients who provided written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atatürk University Coordinator of this site? Confirm its status | Erzurum | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.